TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
Freedman R, Gelman R, Wefel J, Krop I, Melisko M, Lowe A, Agar N, Blackwell K, Connolly R, Niravath P, Van Poznak C, Puhalla S, Ryabin N, Lawler E, Ibrahim N, Liu M, Wolff A, Winer E, Lin N. TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM). Journal Of Clinical Oncology 2014, 32: 528-528. DOI: 10.1200/jco.2014.32.15_suppl.528.Peer-Reviewed Original ResearchHuman epidermal growth factor receptor 2 breast cancerPhase II trialBrain metastasesII trialBreast cancerPatientsMetastasisNeratinibCancerTrials